Metrics to compare | 002826 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship002826PeersSector | |
|---|---|---|---|---|
P/E Ratio | 36.3x | 29.4x | −0.4x | |
PEG Ratio | 0.23 | 0.51 | 0.00 | |
Price/Book | 4.0x | 2.5x | 2.6x | |
Price / LTM Sales | 5.1x | 4.2x | 3.1x | |
Upside (Analyst Target) | - | 25.2% | 48.8% | |
Fair Value Upside | Unlock | 12.0% | 5.7% | Unlock |
Tibet AIM Pharm. Inc. engages in the research and development, manufacturing, and sale of medical products in China. The company’s products include Miglitol tablets for diabetes; ethnic medicine products, suitable for treating breast lobular hyperplasia, uterine fibroids, and ovarian cysts; medicines for gynecology and obstetrics; and Gualoupi injection, Nalmefene hydrochloride injection, and Carbetocin injection. It also provides Domperidone tablets for treatment of indigestion, abdominal bloating, belching, nausea, vomiting, and abdominal distension and pain; Montmorillonite powder for chronic diarrhea; and Hongjin Xiaojie tablets and Aceclofenac Enteric-Coated tablets, as well as for the treatment of antibiotics, antiallergic, and digestive systems. Tibet AIM Pharm. Inc. was founded in 2003 and is based in Lhasa, China.